Örmeci, AslıAydın, YücelŞumnu, AbdullahBaran, BülentMutluay Soyer, ÖzlemPınarbaşı, BinnurGöktürk, SuutGüllüo?lu, MineÖnel, DeryaBadur, SelimAkyüz, FilizKaraca, ÇetinDemir, KadirBeşışık, FatihKaymakoğlu, Sabahattin10.07.20192019-07-1010.07.20192019-07-102016Örmeci, A., Aydın, Y., Şumnu, A., Baran, B., Mutluay Soyer, Ö., Pınarbaşı, B. ... Kaymakoğlu, S. (2016). Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels. 52, 68-73. https://dx.doi.org/10.1016/j.ijid.2016.09.0071201-97121878-3511https://dx.doi.org/10.1016/j.ijid.2016.09.007https://hdl.handle.net/20.500.12511/2789WOS: 000389516600014PubMed ID: 27619844Objectives: Serum alanine aminotransferase (ALT) is a controversial marker for disease monitoring in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. The aim of this study was to determine the fibrosis stage and histological activity index (HAI) in HBeAg-negative CHB patients with persistently normal ALT (PNALT) and high serum HBV DNA (>= 2000 IU/ml) and to investigate clinical risk factors for the requirement of treatment through the examination of liver biopsy specimens. Methods: HBeAg-negative CHB patients with PNALT (<= 40 IU/l) and high serum HBV DNA (>= 2000 IU/ml) were included. HBV fibrosis stage and HAI were scored according to the Ishak system. Multivariate logistic regression analysis was used to estimate the independent risk factors for fibrosis stage >= 2 and/or HAI >= 6. Receiver operating characteristic curve analysis was used to determine an optimal age cut-off for liver biopsy. Results: A total 120 patients were enrolled. These patients had a mean HBV DNA level of 123 680 +/- 494 500 IU/ml; the HBV DNA load was 2000-20 000 IU/ml in 68 patients (56.6%) and >= 20 000 IU/ml in 52 (43.4%). Eighteen patients (15%) had moderate-to-severe histological activity (HAI >= 6). Forty-three patients (35.9%) had a fibrosis stage >= 2. Forty-eight patients (40%) had a fibrosis stage >= 2 and/or HAI >= 6. On multivariate logistic regression analysis, independent variables associated with fibrosis stage >= 2 and/or HAI >= 6 included age and HBV DNA viral load. Patients with HBV DNA 2000-20 000 IU/ml were more likely to require treatment compared to those with a viral load >= 20 000 IU/ml. The optimal age cut-off to predict fibrosis stage >= 2 and/or HAI >= 6 was 46 years. Conclusions: Significant liver damage was detected in 40% of CHB patients with PNALT and high HBV DNA upon biopsy. Age and HBV DNA viral load were independent predictors of significant liver damage. A biopsy to determine the degree of liver damage is advisable for CHB patients older than 46 years.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalinfo:eu-repo/semantics/openAccessChronic Hepatitis BHBeAg-NegativePersistently Normal ALTArticle52687310.1016/j.ijid.2016.09.007Q2Q1